Zobrazeno 1 - 10
of 134
pro vyhledávání: '"GUANGQIANG ZHAO"'
Autor:
Mingsheng Ma, Wei Wang, Li Li, Xiaoyan Wang, Qiubo Huang, Chen Zhou, Yunchao Huang, Guangqiang Zhao, Lianhua Ye
Publikováno v:
Translational Oncology, Vol 46, Iss , Pp 102018- (2024)
Invasion and migration are the primary factors for mortality in lung adenocarcinoma (LUAD) patients. The precise role of RNA-binding motif protein15 (RBM15)-mediated m6A modification in LUAD is not yet fully clarified. This research aims to elucidate
Externí odkaz:
https://doaj.org/article/ac20db17b539400aa668091b804aca68
Autor:
Rui He, Chao Ming, Yujie Lei, Wanling Chen, Lianhua Ye, Guangjian Li, Xiangwu Zhang, Boyi Jiang, Teng Zeng, Yunchao Huang, Guangqiang Zhao
Publikováno v:
The Clinical Respiratory Journal, Vol 18, Iss 1, Pp n/a-n/a (2024)
Abstract In minimally invasive thoracoscopic surgery, for solitary pulmonary nodules (SPNs) far from the pleura, it is difficult to resected by only relying on imaging data, and effective preoperative localization can significantly improve the succes
Externí odkaz:
https://doaj.org/article/b4255b4292bc4dab8a2afae3ad524eda
Publikováno v:
Chinese Journal of Lung Cancer, Vol 26, Iss 5, Pp 359-368 (2023)
Background and objective Xuanwei and Fuyuan are rural counties, located in the late Permian coal poly area of eastern Yunnan and western Guizhou, where lung cancer mortality rates are among the highest in the China, with similarity for both men and w
Externí odkaz:
https://doaj.org/article/dfc5bc67a3644eb7be64b8a0c18426d0
Autor:
Jie Zhao, Zhenghai Shen, Yunchao Huang, Guangqiang Zhao, Wei Wang, Yantao Yang, Chen Zhou, Lianhua Ye
Publikováno v:
BMC Surgery, Vol 23, Iss 1, Pp 1-13 (2023)
Abstract Background Although surgery has been widely applied for SPLC therapy, there is still no uniform treatment approach. Whether SPLC and primary lung cancer have similar prognostic characteristics remains controversial. Herein, based on a system
Externí odkaz:
https://doaj.org/article/51f66d04d79f452b9a29665ca4aa3038
Autor:
Yanping Lin, Long Chen, Rong Li, Xin Liu, Quan Li, Jingjing Cai, Yaxi Du, Guangqiang Zhao, Xiaoxiong Wang, Zhenghai Shen, Yedan Liao, Yang Chen, Lin Xie, Yongchun Zhou, Yunchao Huang
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
ImportancePatients with EGFR mutations who have advanced-stage non-small cell lung cancer (NSCLC) already receive tyrosine kinase inhibitors (TKIs) as the standard first-line therapy. Notably, Yunnan is a regional high incidence area of lung cancer i
Externí odkaz:
https://doaj.org/article/dd49f0763f6c46f88b846d11681bacee
Publikováno v:
World Journal of Surgical Oncology, Vol 21, Iss 1, Pp 1-11 (2023)
Abstract Aims Hematological markers that can be used for prognosis prediction for stage I lung adenocarcinoma (LUAD) are still lacking. Here, we examined the prognostic value of a combination of the red cell distribution width (RDW) and carcinoembryo
Externí odkaz:
https://doaj.org/article/45c22ca87fa74f30a85e8cf0f81ce38c
Autor:
Ruke TANG, Lina BI, Bingquan XIANG, Lianhua YE, Ying CHEN, Guangjian LI, Guangqiang ZHAO, Yunchao HUANG
Publikováno v:
Chinese Journal of Lung Cancer, Vol 26, Iss 1, Pp 22-30 (2023)
Lung cancer is the leading cause of cancer death in the world today, and adenocarcinoma is the most common histopathological type of lung cancer. In May 2021, World Health Organization (WHO) released the 5th edition of the WHO classification of thora
Externí odkaz:
https://doaj.org/article/2c83a19f38744db0b423b8cd83824423
Autor:
Jie Zhang, Yueyin Pan, Qin Shi, Guojun Zhang, Liyan Jiang, Xiaorong Dong, Kangsheng Gu, Huijuan Wang, Xiaochun Zhang, Nong Yang, Yuping Li, Jianping Xiong, Tienan Yi, Min Peng, Yong Song, Yun Fan, Jiuwei Cui, Gongyan Chen, Wei Tan, Aimin Zang, Qisen Guo, Guangqiang Zhao, Ziping Wang, Jianxing He, Wenxiu Yao, Xiaohong Wu, Kai Chen, Xiaohua Hu, Chunhong Hu, Lu Yue, Da Jiang, Guangfa Wang, Junfeng Liu, Guohua Yu, Junling Li, Jianling Bai, Wenmin Xie, Weihong Zhao, Lihong Wu, Caicun Zhou
Publikováno v:
Cancer Communications, Vol 42, Iss 1, Pp 3-16 (2022)
Abstract Background Lipusu is the first commercialized liposomal formulation of paclitaxel and has demonstrated promising efficacy against locally advanced lung squamous cell carcinoma (LSCC) in a small‐scale study. Here, we conducted a multicenter
Externí odkaz:
https://doaj.org/article/6390005c415f4ea5b107038b3eac3a40
Autor:
Yuhui Ma, Hutao Shi, Guangqiang Zhao, Xin Liu, Jingjing Cai, Guangjian Li, Wanlin Chen, Yujie Lei, Lianhua Ye, Chaojiang Fu, Li Zhao, Yongchun Zhou, Yunchao Huang
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundChina’s southwestern region, Qujing, harbors a high incidence of non-small cell lung cancer (NSCLC) and related mortality. This study was designed to reveal the impact of an immune-related prognostic signature (IRPS) on advanced NSCLC in
Externí odkaz:
https://doaj.org/article/c8ce58c908534506820a59021c130f46
Autor:
Wei Wang, Mingsheng Ma, Li Li, Yunchao Huang, Guangqiang Zhao, Yongchun Zhou, Yantao Yang, Yichen Yang, Biying Wang, Lianhua Ye
Publikováno v:
Translational Oncology, Vol 25, Iss , Pp 101500- (2022)
Distant metastasis is the main cause of death in non-small cell lung cancer (NSCLC) patients. The mechanism of metastasis-associated protein 1(MTA1) in NSCLC has not been fully elucidated. This study aimed to reveal the mechanism of MTA1 in the invas
Externí odkaz:
https://doaj.org/article/406a4402e3be41418ff28037c4ed2aab